In 2019, Synchron was in the midst of a $10 million series A funding when they made headlines with their first human implant. Founder and CEO Thomas Oxley expressed his excitement about the potential of unlocking the brain’s computational power, stating that this was just the beginning for the industry. Fast forward to last week, and Synchron announced a substantial $200 million Series D funding round to propel their pivotal clinical trial and expand operations to San Diego.
I had the opportunity to sit down with Oxley to delve deeper into Synchron’s journey and the evolution of brain-computer interface (BCI) technology. Looking back at the company’s progress since 2019, milestones such as FDA Breakthrough Designation for their Stentrode in 2020, a $40 million Series B led by Khosla Ventures in 2021, and the commencement of an early feasibility study in 2022 demonstrate Synchron’s commitment to advancing BCI capabilities.
With a total funding of $345 million to date and a reported valuation of around a billion dollars, Synchron’s Series D attracted a diverse group of investors. Oxley highlighted the significance of long-term backers who share the company’s vision for the future of BCI technology. The addition of new board members and key executives, coupled with plans to establish a manufacturing facility in Southern California, underscore Synchron’s strategic growth trajectory.
As Synchron sets its sights on developing a next-generation BCI system, Oxley hinted at a minimally invasive, high-channel count interface that promises to revolutionize brain connectivity. This forward-looking approach aligns with Synchron’s core principles of accessibility, comprehensive brain coverage, and data-driven innovation.
Reflecting on market trends and industry dynamics, Oxley emphasized the need for sustainable growth in the BCI sector, cautioning against inflated valuations that could lead to a bubble burst. He also touched on emerging fields such as biohybrid interfaces and the potential for consumer applications in neurotechnology, citing Apple’s role in cognitive enhancement through products like Airpods.
In closing, Synchron’s Series D funding marks a significant milestone in the company’s journey towards commercialization and regulatory approval. With a focus on enhancing their existing technology and expanding market reach, Synchron remains at the forefront of the BCI landscape, poised to shape the future of neural interfaces and cognitive augmentation.
